Learn More
Description
- This novel enhancer is easily integrated into existing workflows, and it produces 2 to 4 times higher titers across a range of serotypes, cellular growth media formulations, and transfection platforms.
- RevIT™ AAV Enhancer can further drive down upstream manufacturing costs by permitting the use of lower levels of plasmid DNA while maintaining high-quality titers.
- Continual improvements in both upstream and downstream AAV manufacturing processes will allow the next generation of gene therapies to reach a broader audience.
Specifications
Specifications
| Cell Type | 293-derived Cells |
| Format | Tube |
| Promoter | None (Promoterless) |
| Transfection Technique | Chemical Transfection |
| Product Type | AAV Enhancer |
| Sterility | Sterile |
| Volume (Metric) | 10 x 1.5 mL |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.